C
CTNM
vs
S&P 500
S&P 500
Over the past 12 months, CTNM has underperformed S&P 500, delivering a return of -15% compared to the S&P 500's +14% growth.
Stocks Performance
CTNM vs S&P 500
Performance Gap
CTNM vs S&P 500
Performance By Year
CTNM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Contineum Therapeutics Inc
Glance View
Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
